Characterising the innate immune response to decellularised extracellular matrix-based heart valve and aortic implants (C04*)

脱细胞人心脏瓣膜（DHV）在生物相容性和耐久性方面是一种很有前途的心脏瓣膜替代治疗方法。尽管如此，在一些患者中已经观察到主动脉dhv的早期和晚期变性，一些研究暗示在这一过程中对脱细胞细胞外基质（dECM）的免疫反应。在这个项目中，我们的目标是描述对dECM移植材料的免疫反应，并研究其调节如何影响基于dECM的植入物的宿主整合。总之，我们希望为靶向药物治疗建立分子基础，以提高dhv的整合、生物相容性和持久性。

Decellularised human heart valves (DHV) are a promising therapeutic approach for heart valve replacement in terms of biocompatibility and durability. Nonetheless, early and late degeneration of aortic DHVs has been observed in some patients, with several studies implicating the immune response to the decellularised extracellular matrix (dECM) in this process. In this project, we aim to characterise the immune response to dECM graft material and investigate how its modulation may affect host integration of dECM-based implants. Altogether, we hope to establish the molecular groundwork for targeted pharmacological therapies to improve integration, biocompatibility, and durability of DHVs.